Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects

A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects

This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.

Inclusion Criteria:

• BMI (body mass index) between 19-29 kg/m^2 (both inclusive)
• Fasting blood glucose between 3.8-6.0 mmol/L (both inclusive)
• Non-smokers

Exclusion Criteria:

• Subjects with a first-degree relative with diabetes mellitus
• Subjects smoke 5 cigarettes or more per day